Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Cognition Therapeutics, Inc. - Common Stock (NQ: CGTX )

0.7703 +0.0010 (+0.13%)
Streaming Delayed Price Updated: 12:24 PM EST, Jan 23, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Press Releases about Cognition Therapeutics, Inc. - Common Stock

< Previous 1 2 3 Next >
Cognition Therapeutics Announces Closing of $11.5 Million Public Offering of Common Stock
From Cognition Therapeutics, Inc.
Via GlobeNewswire
Cognition Therapeutics Announces Proposed Public Offering of Common Stock
From Cognition Therapeutics, Inc.
Via GlobeNewswire
Cognition Therapeutics Presents Analyses at AD/PD™ 2024 Correlating Proteomic Findings with Treatment Effect of CT1812 in Alzheimer’s Disease Studies
From Cognition Therapeutics, Inc.
Via GlobeNewswire
Cognition Therapeutics to Present at the TD Cowen Health Care Conference
From Cognition Therapeutics, Inc.
Via GlobeNewswire
New Publication Identifies Key Proteins Involved in Amyloid Oligomer Binding and Supports Mechanism of CT1812
From Cognition Therapeutics, Inc.
Via GlobeNewswire
Cognition Therapeutics CEO Issues Letter to Shareholders
From Cognition Therapeutics, Inc.
Via GlobeNewswire
Cognition Therapeutics Releases New Episode of “Conversations” Podcast Recorded at CTAD with Quantitative EEG Experts, Drs Willem de Haan and Philip Scheltens
From Cognition Therapeutics, Inc.
Via GlobeNewswire
Cognition Therapeutics Presents Preclinical Data Identifying Pathways Impacted by Sigma-2 Receptor Modulators in Alzheimer’s and Parkinson’s Diseases
From Cognition Therapeutics, Inc.
Via GlobeNewswire
Cognition Therapeutics Completes Enrollment in Phase 2 SHINE Study of CT1812 in Mild-to-Moderate Alzheimer’s Disease
From Cognition Therapeutics, Inc.
Via GlobeNewswire
Cognition Therapeutics Reports Third Quarter 2023 Financial Results and Provides Business Update
From Cognition Therapeutics, Inc.
Via GlobeNewswire
Cognition Therapeutics and Collaborators at Yale and ACTC Announce Oral Late-breaking Presentation on the START Study in Early Alzheimer’s Disease at CTAD
From Cognition Therapeutics, Inc.
Via GlobeNewswire
Cognition Therapeutics Presents Complete EEG Findings from SEQUEL Study of CT1812 in Mild-to-Moderate Alzheimer’s Disease at CTAD
From Cognition Therapeutics, Inc.
Via GlobeNewswire
Cognition Therapeutics Presents New Data at CTAD Conference from Advancing Pipeline Across Multiple CNS Indications
From Cognition Therapeutics, Inc.
Via GlobeNewswire
Cognition Therapeutics Announces New Conversations Episode on Therapeutic Strategies to Protect the Retina in Dry AMD
From Cognition Therapeutics, Inc.
Via GlobeNewswire
Cognition Therapeutics Announces Participation in Upcoming September Conferences
From Cognition Therapeutics, Inc.
Via GlobeNewswire
Cognition Therapeutics Reports Second Quarter 2023 Financial Results and Business Update
From Cognition Therapeutics, Inc.
Via GlobeNewswire
Cognition Therapeutics to Report Second Quarter 2023 Results in Conference Call on Tuesday, August 8, 2023
From Cognition Therapeutics, Inc.
Via GlobeNewswire
Cognition Therapeutics Announces Dosing of First Patient in MAGNIFY Study of Oral CT1812 for Geographic Atrophy Secondary to Dry AMD
From Cognition Therapeutics, Inc.
Via GlobeNewswire
Cognition Therapeutics and the Alzheimer's Clinical Trials Consortium Initiate First Clinical Site in the Phase 2 START Study in Early Alzheimer’s Disease
From Cognition Therapeutics, Inc.
Via GlobeNewswire
Cognition Therapeutics Announces Positive Topline Results for CT1812 Phase 2 SEQUEL Study for Mild-to-Moderate Alzheimer’s Disease
From Cognition Therapeutics, Inc.
Via GlobeNewswire
Cognition Therapeutics to Host Call and Webcast to Discuss Topline Results from CT1812 Phase 2 SEQUEL Study on June 28, 2023
Call and webcast will take place at 8:00am ET 
From Cognition Therapeutics, Inc.
Via GlobeNewswire
Cognition Therapeutics Invited to Participate on Panel During Cantor Fitzgerald Brain Week 2023 on Novel Alzheimer’s Disease Approaches
From Cognition Therapeutics, Inc.
Via GlobeNewswire
Cognition Therapeutics Continues Investor Engagement in June with Presentations at World Medical Innovation and Longwood Healthcare Leaders Conferences
From Cognition Therapeutics, Inc.
Via GlobeNewswire
Cognition Therapeutics Latest Episode of “Conversations” Podcast Features Biomarker Experts from Gothenburg University, Emory and Amsterdam UMC
From Cognition Therapeutics, Inc.
Via GlobeNewswire
Cognition Therapeutics Publishes Clinical Evidence that CT1812 Displaces Aβ Oligomers from Binding to Neuronal Synapses in Alzheimer’s Disease
- First Human Evidence that CT1812 Selectively Engages Aβ Oligomers 
From Cognition Therapeutics, Inc.
Via GlobeNewswire
Cognition Therapeutics Reports First Quarter 2023 Financial Results and Provides Business Update
From Cognition Therapeutics, Inc.
Via GlobeNewswire
Cognition Therapeutics Appoints John Doyle to the Role of Chief Financial Officer
From Cognition Therapeutics, Inc.
Via GlobeNewswire
Cognition Therapeutics to Present Analysis Showing Impact of CT1812 on Pathways Implicated in Dry Age-related Macular Degeneration at ARVO 2023
From Cognition Therapeutics, Inc.
Via GlobeNewswire
Cognition Therapeutics Announces New Scientific Publication on Therapeutic Potential of Targeting Sigma-2 Receptor for Age-related Degenerative Diseases
International Journal of Molecular Science Review Presents Mechanistic Rationale for Sigma-2 Receptor Modulation in Alzheimer’s Disease, Dementia with Lewy Bodies and Geographic Atrophy 
From Cognition Therapeutics, Inc.
Via GlobeNewswire
Cognition Therapeutics Presents Proteomic Biomarker Data Demonstrating Prominent Effects of CT1812 in Altering Underlying Alzheimer’s Disease Processes
From Cognition Therapeutics, Inc.
Via GlobeNewswire
< Previous 1 2 3 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.